View More Recent Stories

Apr 8, 2024 08:30AM Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Mar 26, 2024 08:32AM Entera Bio Ltd. (ENTX) Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program
Mar 26, 2024 08:30AM Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Mont
Mar 20, 2024 08:03AM Entera Bio Ltd. (ENTX) Announces Robust Pharmacokinetic Data for Oral GLP-2 Peptide Tablet Treatment
Mar 20, 2024 08:00AM Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Mar 8, 2024 04:05PM Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
View More Recent Stories